Cholangiocarcinoma
Conditions
Interventions
Index test:The effectiveness of lipid biomarkers in bile for diagnosing cholangiocarcinoma and benign bile duct diseases based on bile lipidomics analysis.
Sponsors
The second hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Benign bile duct disease group: (1) Patients confirmed by imaging and/or postoperative pathology to have benign bile duct diseases (further divided into inflammatory bile duct diseases, including recurrent suppurative cholangitis, primary biliary cholangitis, primary sclerosing cholangitis, etc., and non-inflammatory diseases); (2) Patients whose age and sex match those in the malignant bile duct disease group; (3) Patients planning to undergo ERCP treatment; (4) Patients who voluntarily participate in the study and sign the informed consent form. 2. Malignant bile duct tumor group: (1) Patients confirmed by cytology or histopathology to have malignant bile duct tumors; (2) Patients with definite clinical or pathological staging according to the TNM staging system; (3) Patients planning to undergo ERCP treatment; (4) Patients who voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Benign Bile Duct Disease Group: (1) Pathologically confirmed as malignant or high-grade dysplasia before or after surgery; (2) Imaging suggests possible malignancy; (3) Presence of malignant tumors in other organs; (4) Pregnant or breastfeeding women; (5) Sepsis caused by bile duct infection; (6) People prone to bleeding or with coagulation disorders; (7) Other situations that the researchers judge as unsuitable for participating in this study. 2. Bile Duct Malignant Tumor Group: (1) Pathological type is not cholangiocarcinoma; (2) Has other malignant tumors (e.g., pancreatic cancer); (3) Metastatic cancer; (4) Have received any known anticancer treatment; (5) Sepsis caused by bile duct infection; (6) Diagnosis is unclear due to lack of clinical information or insufficient follow-up time; (7) Pregnant or breastfeeding women; (8) People prone to bleeding or with coagulation disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity ;accuracy; | — |
Countries
China
Contacts
Public ContactZhang Rixin
The second hospital of Dalian Medical University
Outcome results
None listed